Shield Raises Reduced IPO As Anemia Drug Nears Approval
This article was originally published in Scrip
Executive Summary
Shield Therapeutics, which is expecting EU approval for its novel oral iron replacement drug Feraccru (ST10, ferric maltol) during this quarter, has raised £32.5m in an initial public offering on the AIM market of the London Stock Exchange.